Verseon Corp. | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
27.50
220.90
392.90
Gross Income
27.50
220.90
392.90
SG&A Expense
6,356.80
12,628.80
16,249.90
EBIT
6,384.30
12,849.60
16,642.80
Non Operating Income/Expense
1,224.60
1,931.40
436.40
Interest Expense
117.20
2.20
-
Pretax Income
5,035.30
14,442.30
15,831.40
Consolidated Net Income
5,035.30
14,442.30
15,831.40
Net Income
5,034.00
14,438.60
15,829.80
Net Income After Extraordinaries
5,034.00
14,438.60
15,829.80
Net Income Available to Common
5,034.00
14,438.60
15,829.80
EPS (Basic)
0.04
0.10
0.10
Basic Shares Outstanding
136,092.50
151,339.30
151,436.60
EPS (Diluted)
0.04
0.10
0.10
Diluted Shares Outstanding
136,092.50
151,339.30
151,436.60
EBITDA
6,356.80
12,628.80
16,249.90
Non-Operating Interest Income
241.50
340.90
375.10
Minority Interest Expense
1.30
3.70
1.60

About Verseon

View Profile
Address
47071 Bayside Parkway
Fremont California 94538
United States
Employees -
Website http://www.verseon.com
Updated 09/14/2018
Verseon Corp. engages in the development and design of pharmaceutical products. It focuses on drug discovery technology to seed a growing portfolio of programs targeting diverse disease areas, currently consisting of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The company was founded by Eniko Fodor, David Kita, and Adityo Prakash in 2002 and is headquartered in Fremont, CA.